ERBB2 and neoplasm: These include adjuvant capecitabine in TNBC (CREATE-X), T-DM1 in HER2-positive disease with residual tumor (KATHERINE), and perioperative pembrolizumab in high-risk TNBC (KEYNOTE-522).